Our Team

The founding of ALX Oncology was based upon technology invented at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1

ALX Oncology is an independent, private biotechnology company. Since May 2015, we have raised a total of $61 million in funding, which was led by venBio and joined by Lightstone Ventures and Stanford University.

Emma Abellana

Senior Director, Finance and Controller

Melissa Aquino

Executive Assistant

Oscar Bisnar

Senior Accountant

Michael Chang, Ph.D.

Vice President, Operations

Amy Chen

Senior Scientist

Laura Doyle

Scientist

Philip Fanning, Ph.D.

Senior Director, Clinical Science

Danielle Fontaine

Facilities Assistant

Ons Harrabi

Senior Scientist

Declan Hayes

Director of Strategy and Corporate Development

Tracy Kuo, Ph.D.

Director, Biology

Jaume Pons, Ph.D.

President and Chief Executive Officer

Sophia Randolph, M.D., Ph.D.

Chief Medical Officer

Emma Sangalang

Senior Scientist

Janet Sim, Ph.D.

Vice President, Protein Science

Hank Stern

Vice President, Chemistry, Manufacturing, and Controls

Hong I. Wan, Ph.D.

Chief Scientific Officer

Michael Warner, J.D., Ph.D.

Acting General Counsel

 

Reference

  1. Kipp Weiskopf, et al. Science 341, 88 (2013);
    DOI: 10.1126/science.1238856;
    Abstract link: http://www.ncbi.nlm.nih.gov/pubmed/23722425